Ozempic(Semaglutide)
NVO
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Novo Nordisk A/S
$12.97B
Medicare cost, 2024
$12.97B
Medicare cost, 2024
Medicare drug plans spent $13.0 billion on Ozempic (semaglutide) in 2024, for 10.4 million prescriptions and refills filled by 2.0 million patients. It ranks 2nd among all drugs by Medicare drug plan spending. Spending rose 41% from 2023 to 2024. Texas accounts for the most spending ($1.2 billion, 9% of the total).
Medicare cost, 2024
$12.97B
+41.1% from 2023
Prescriptions
10.4M
$1,245.09 per claim
Patients
2.0M
286,517 prescribers
Total spending, 2024
$12.97B
$6,642.45 per patient
Questions and answers
How much does Medicare spend on Ozempic?
Medicare prescription drug plans paid $12.97B for Ozempic in 2024, for 10,413,554 prescriptions and refills to 1,951,892 patients (up 41.1% from 2023). The average cost per claim was $1,245.09.
Which state spends the most on Ozempic?
Texas had the highest Medicare cost for Ozempic in 2024: $1.18B for 912,298 claims, followed by California ($1.10B).
Who prescribes Ozempic the most?
Eugenio Angueira-Serrano, endocrinology in Miami, FL, had the highest Medicare cost for Ozempic in 2024: 5,444 claims costing $5.8M.
Who makes Ozempic?
Ozempic is made by Novo Nordisk A/S (NVO), listed in the Medicare spending data as Novo Nordisk.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Ozempic was $12.97B in 2024, the highest year shown.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Ozempic, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Eugenio Angueira-Serrano Miami, FL | Endocrinology | 5,444 | 885 | $5.8M |
| Stella Ilyayeva Rego Park, NY | Internal Medicine | 3,061 | 582 | $3.2M |
| Monica G Robles Anniston, AL | Endocrinology | 1,675 | 379 | $2.5M |
| Syed A Hassan Harlingen, TX | Endocrinology | 1,506 | 380 | $2.4M |
| Bashar G Saad San Dimas, CA | Endocrinology | 2,138 | 447 | $2.4M |
| Lane M Frey Thibodaux, LA | Endocrinology | 1,296 | 306 | $2.3M |
| Ronald B Villanueva Lakewood, NJ | Endocrinology | 1,154 | 292 | $2.3M |
| Stephan Kowalyk Greensburg, PA | Endocrinology | 1,983 | 348 | $2.3M |
| Kandaswamy Jayaraj Beaumont, TX | Endocrinology | 1,321 | 301 | $2.1M |
| Brian E Burtch Willoughby, OH | Endocrinology | 1,281 | 308 | $2.0M |
| Cheng-Yang C Tuan San Francisco, CA | Endocrinology | 1,180 | 260 | $2.0M |
| Vinay Kapoor Bayside, NY | Endocrinology | 994 | 243 | $1.9M |
| Irina A Urusova Los Angeles, CA | Endocrinology | 1,999 | 256 | $1.9M |
| Alisha Mason Ripley, MS | Family Practice | 724 | 280 | $1.9M |
| Phong H Bui Fountain Valley, CA | Internal Medicine | 1,314 | 230 | $1.9M |
| Ralph Oiknine Chesterfield, MO | Endocrinology | 1,073 | 243 | $1.9M |
| Juan D Palacios Merchan Edinburg, TX | Endocrinology | 1,382 | 268 | $1.8M |
| Farhad Farjoudi San Diego, CA | Endocrinology | 1,165 | 273 | $1.8M |
| Ahmed F Al Jebawi Anderson, IN | Endocrinology | 1,152 | 252 | $1.8M |
| Kalyani Regeti North Port, FL | Endocrinology | 903 | 233 | $1.8M |
| Sharon H Kim Bronx, NY | Endocrinology | 1,256 | 233 | $1.7M |
| Ahmet B Ergin Port St Lucie, FL | Endocrinology | 1,108 | 278 | $1.7M |
| Anju Gurung Fayetteville, NC | Internal Medicine | 1,017 | 222 | $1.7M |
| Benito A Marranzini El Paso, TX | Endocrinology | 905 | 236 | $1.7M |
| Nidhi Jain Little Rock, AR | Endocrinology | 1,539 | 280 | $1.7M |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 179,831 | 3,410,067 | 780,031 | $4.63B |
| 2023 | 254,476 | 6,925,667 | 1,463,887 | $9.19B |
| 2024 | 286,517 | 10,413,554 | 1,951,892 | $12.97B |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Novo Nordisk | 10,417,182 | $12.97B |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 8
- RxNorm concept IDs
- 2398841, 2398842, 2599362, 2599365, 2619152
- Application numbers
- NDA209637
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 78,023 side-effect reports named semaglutide, the active ingredient of Ozempic (reports from 2013 on). 39,105 of them (50.1%) were serious, 1,364 named a death and 15,565 named a hospital stay. The reactions named most often were nausea, off label use and vomiting. 67,168 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
78,023
20,019 in 2025 (+39.9% from 2024)
Serious
50.1%
39,105 reports
Deaths named
1,364
1.7% of reports
Hospital stays
15,565
19.9% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Ozempic?
78,023 reports from 2013 through September 2026 named semaglutide, the active ingredient of Ozempic. 39,105 of them (50.1%) were serious, 1,364 named a death and 15,565 named a hospital stay.
What are the most reported side effects of Ozempic?
11,150 reports named nausea, the reaction named most often, followed by off label use (7,890) and vomiting (7,332). In the last 5 years the reaction named most often was nausea (9,222 reports). A report can name several reactions.
How many side-effect reports named Ozempic in 2025?
20,019 reports were received in 2025 (+39.9% from 2024). 2026 so far: 17,010 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Ozempic caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Ozempic caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with semaglutide: Rybelsus, Wegovy
- Makers on the stock market:
NVO·NVO drug pipeline - Drug approvals (3 approvals on file for semaglutide) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (semaglutide) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.